News
(2)April 2026
ALT raises $225 million selling stock and warrants to fund development
# 🧾 What This Document Is This is a **prospectus supplement**, a legal filing that adds the specific details of a new stock offering to a previously approved "shelf" registration. Think of it like a detailed menu addendum for a restaurant that already has a general license to serve food. 👉 In si
Altimmune files for capital raise citing MASH and ALD drug candidate success
# 🧾 What This Document Is 📑 This document is a Preliminary Prospectus Supplement, filed on April 22, 2026. Essentially, it is a detailed legal roadmap informing investors about the company and the specific securities Altimmune, Inc. plans to sell. Since it is a "preliminary" document, it means the
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.